Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Currency in USD	2026
Operating Income	-220.5 Million
Income Before Tax	-215.7 Million
Income Tax Expense	N/A
Net Income	-215.7 Million
Eps	-0.28
Epsdiluted	-0.28
Weighted Average Shs Out	778.18 Million
Weighted Average Shs Out Dil	778.18 Million
Research And Development Expenses	157.73 Million
Selling General And Administrative Expenses	N/A
Depreciation And Amortization	46.00 Thousand
Interest Expense	N/A
Interest Income	N/A
Net Interest Income	N/A
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	N/A
Ebitda	-220.45 Million
Source	edgar
Ebit	-220.5 Million

Summit Therapeutics Inc. Annual Reports (10-K)